摘要
胰腺癌是一种恶性程度高、患者总体预后不良的肿瘤。高异质性、复杂的肿瘤微环境、耐药性更是加剧了胰腺癌治疗的困难性。目前,吉西他滨联合卡培他滨、白蛋白紫杉醇等以及FOLFIRINOX是可切除或晚期转移性胰腺癌的标准化学疗法。鉴于化疗疗效有限且伴随毒副作用,近来靶向药物及免疫治疗药物逐渐引起重视并取得一定进展。本文将对胰腺癌的化疗药物、靶点及靶向药物、免疫治疗药物进行系统综述。
Pancreatic cancer is a highly malignant tumor with a poor prognosis.It is very hard to treat pancreatic cancers for their high heterogeneity,complex tumor microenvironment,and drug resistance.Currently,gemcitabine plus nab-paclitaxel,capecitabine and FOLFIRINOX are standard chemotherapy for resectable or advanced metastatic pancreatic cancer.Considering the limited efficacy and toxic side effects of chemotherapy,targeted and immune drugs have gradually attracted attention and made some progress.In this article,we systematically reviewed the chemotherapeutic drugs,targets and related targeted drugs,and immunotherapy drugs for pancreatic cancer.
作者
杨红
李婉
李莎
任利文
张宜之
杨艺辉
葛彬彬
郑湘锦
刘金宜
张森
杜冠华
王金华
YANG Hong;LI Wan;LI Sha;REN Li-wen;ZHANG Yi-zhi;YANG Yi-hui;GE Bin-bin;ZHENG Xiang-jin;LIU Jin-yi;ZHANG Sen;DU Guan-hua;WANG Jin-hua(Beijing Key Laboratory of Drug Target Identification and Drug Screening,Institute of Materia Medica,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100050,China)
出处
《药学学报》
CAS
CSCD
北大核心
2023年第1期9-20,共12页
Acta Pharmaceutica Sinica
基金
北京市自然科学基金资助项目(7212157)
中国医学科学院创新工程基金(2021-I2M-1-029,2022-I2M-JB-011)。
关键词
胰腺癌
化疗
药物靶点
靶向治疗
免疫治疗
pancreatic cancer
chemotherapy
drug target
targeted therapy
immunotherapy
